Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | STAMBP | O95630 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452692 | 1.00 | EGLN1 (0.46) | EGLN1FTOEGLN3KMT2AMEN1 | |
| SCHEMBL24257704 | 0.91 | PPARG (0.39) | EGLN1FTOEGLN3KMT2AMEN1 | |
| SCHEMBL30453029 | 0.91 | PPARG (0.39) | EGLN1FTOEGLN3KMT2AMEN1 | |
| SCHEMBL30452826 | 0.88 | GAA (0.48) | EGLN1KMT2AMEN1L3MBTL1PPID | |
| SCHEMBL24257806 | 0.88 | EGLN1 (0.44) | EGLN1FTOKMT2AMEN1L3MBTL1 | |
| SCHEMBL24257686 | 0.88 | GAA (0.48) | EGLN1KMT2AMEN1L3MBTL1PPID | |
| SCHEMBL30452640 | 0.86 | EGLN1 (0.46) | EGLN1EGLN3KMT2AMEN1L3MBTL1 | |
| SCHEMBL24257548 | 0.86 | EGLN1 (0.46) | EGLN1EGLN3KMT2AMEN1L3MBTL1 | |
| SCHEMBL24257835 | 0.86 | VEGFA (0.49) | EGLN1EGLN3KMT2AMEN1L3MBTL1 | |
| SCHEMBL30452770 | 0.86 | VEGFA (0.49) | EGLN1EGLN3KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885FTO 3079/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.